In Segment A, individuals will get various doses and schedules of oral ABBV-744 tablet to establish Secure dosing routine. Supplemental participants is going to be enrolled at the recognized monotherapy dosign routine. In Section B, members will get oral ruxolitinib and ABBV-744 will be provided as "insert-on" therapy. In Phase https://dominicklkkhf.blog-mall.com/32656166/not-known-details-about-brd4-inhibition-by-abbv-744-in-cancer-research-studies